Clinical Trial

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 3, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.
Trial Details
NCT Number NCT06757335
Lead Sponsor Hinova Pharmaceuticals Inc.
Conditions Breast Cancer
Enrollment 204 participants
Start Date 2025-01-07
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-11-27 (estimated)
Updated on ClinicalTrials.gov 2025-01-03